News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Trends in Smoking Initiation Among Adolescents and Young Adults-United States, 1980-1989

March 1, 1996
Publication
Article
OncologyONCOLOGY Vol 10 No 3
Volume 10
Issue 3

The evaluation of efforts to prevent tobacco use among adolescents requires accurate surveillance of both smoking prevalence and smoking initiation rates. Although several surveillance systems provide timely data about adolescent smoking prevalence, data characterizing rates of smoking initiation among adolescents have been limited. To improve characterization of trends in smoking initiation among young persons, data from the Tobacco Use Supplement of the 1992 and 1993 Current Population Surveys (CPS) were used to estimate smoking initiation rates for persons who were adolescents (age 14 to 17 years) or young adults (age 18 to 21 years) during 1980 to 1989. This report summarizes the results of that analysis.

The evaluation of efforts to prevent tobacco use among adolescentsrequires accurate surveillance of both smoking prevalence andsmoking initiation rates. Although several surveillance systemsprovide timely data about adolescent smoking prevalence, datacharacterizing rates of smoking initiation among adolescents havebeen limited. To improve characterization of trends in smokinginitiation among young persons, data from the Tobacco Use Supplementof the 1992 and 1993 Current Population Surveys (CPS) were usedto estimate smoking initiation rates for persons who were adolescents(age 14 to 17 years) or young adults (age 18 to 21 years) during1980 to 1989. This report summarizes the results of that analysis.

The CPS are monthly surveys of the US civilian, noninstitutionalizedpopulation age equal to or more than 15 years. Approximately 56,000households are surveyed each month; one household respondent providesinformation about all household members age equal to or more than15 years. Questions about tobacco use were added to the September1992, January 1993, and May 1993 monthly surveys. The responserates for the three surveys were 84.7%, 84.9%, and 82.0%, respectively(N = 293,543 household members). To minimize biases that couldresult from discrepancies between self-reports and proxy reportsof smoking behavior, this analysis used data from self-respondentsonly (82% of total sample).

Ever-smokers were defined as respondents who answered "yes"to the question, "Have you smoked at least 100 cigarettesin your entire life?" Ever-smokers were asked, "Howold were you when you started smoking cigarettes fairly regularly?"To restrict the analysis to persons who were adolescents or youngadults for some period during 1980-1989, only respondents aged17-34 years at interview were included. The final sample consistedof 71,321 persons, of whom 27,768 (38.9%) were ever-smokers.

Using the age of respondents at the time of the interview andthe age they reported starting smoking, the age of respondentsand their smoking status were calculated for each year duringthe 1980s. The denominator for the initiation rate for a givenyear was the number of respondents at risk for initiating smokingduring that year (persons already smoking were eliminated fromthe denominator for that year). The numerator was the number ofrespondents who reported initiating smoking during that year.Data were weighted by age, sex, and race/ethnicity to providenational estimates.

Among adolescents, the smoking initiation rate decreased slightlyfrom 1980 (5.4%) through 1984 (4.7%) and then increased through1989 (5.5%); the largest annual increase occurred in 1988 (Figure1). In comparison, among young adults, initiation rates decreasedthroughout the 1980s (Figure 1). For both age groups, initiationrates and trends were similar for males and females.

Editorial Note From the CDC

The findings in this report indicate an increase in the rate ofinitiation of cigarette smoking among adolescents from 1985 through1989, a period during which the rate among young adults declinedand overall prevalence of smoking among adults decreased steadily.One important consequence of the increased rate of initiationamong adolescents will be the increased future burden of tobacco-relateddisease. In particular, because of the increase in initiationsince 1984, it is estimated that an additional 600,000 adolescentsbegan to smoke during 1985 to 1989. Of those adolescents who continueto smoke regularly, approximately 50% will die from smoking-attributabledisease.

Potential reasons for an increase in smoking initiation ratesamong adolescents include a decreased real price of cigarettes,increased levels of disposable income, increased acceptabilityof smoking, and intensified cigarette marketing. However, becausethe real price of cigarettes increased steadily during 1985 to1989 and the real average weekly income among high school seniorsremained stable during this period, cigarettes were less affordableto young persons. In addition, the acceptability of smoking amonghigh school seniors did not increase: During this period therewere increases in the percentages of high school seniors who believedthat cigarettes are harmful, smoking is a "dirty habit,"and becoming a smoker reflects poor judgment, and who reportedthat they "mind being around people who are smoking"and would prefer to date nonsmokers.

Is Advertising the Cause?

The increase in rates of smoking initiation among adolescentsduring 1985 to 1989 may reflect increased real expenditures forcigarette advertising and promotion. The increase in rates occurredduring a period when real expenditures for total cigarette advertisingand promotion* doubled, and expenditures for cigarettepromotion more than quadrupled (Figure 2): from 1980 to 1989,total annual advertising and promotional expenditures (in 1993dollars) increased from $2.1 billion to $4.2 billion, while promotionalexpenditures alone increased from $771 million (37% of total expenditures)to $3.2 billion (76%) (Figure 2). Promotional efforts have beenhighly effective among adolescents. For exam ple, among personsage 12 to 17 years in 1992, approximately 50% of smokers and 25%of nonsmokers reported having received promotional items fromtobacco companies.

An association between overall cigarette marketing expendituresand initiation rates for smoking among adolescents is plausiblefor at least four reasons:

  • First, brand loyalty is usually established with the firstcigarette smoked; therefore, cigarette companies have an economicincentive to encourage first-time smokers to smoke their brands.
  • Second, adolescents are exposed to cigarette advertising andpromotions that employ themes and images that appeal to youngpersons.
  • Third, advertising directly influences brand awareness andattitudes toward smoking among adolescents. Specifically, adolescentssmoke the most heavily advertised brands, and changes in brandpreferences among young persons are associated with changes inbrand-specific advertising expenditures. For example, the JoeCamel campaign introduced nationally in 1988 was associated withan increase in the market share of that specific brand among adolescents.
  • Finally, consumer research suggests that younger persons (ie,age 14 to 17 years) aspire to be young adults; therefore, advertisingand promotional efforts targeted toward young adults may havegreater appeal to adolescents because of their age aspirations.

Although current estimates of smoking initiation rates among adolescentsare not available, from 1991 through 1993, the national prevalenceof smoking increased among eighth and tenth-grade students. Toreverse the trend of increasing smoking initiation rates amongadolescents and to achieve the national health objective for theyear 2000 of reducing the initiation of cigarette smoking by youth(no more than 15% should become regular smokers by age 20; objective3.5), prevention efforts that focus on young persons should beintensified. Such efforts could include making cigarettes lessaffordable by either increasing their real price or by limitingsales to cartons rather than individual packs, enforcing lawsprohibiting the sale and distribution of cigarettes to young persons,conducting mass media campaigns to discourage tobacco use, andeliminating or severely restricting all forms of tobacco productadvertising and promotion to which young persons are likely tobe exposed.

Reported by: K.M. Cummings, PhD, D Shah, MS, Roswell ParkCancer Institute, Buffalo, New York; D.R. Shopland, National CancerInstitutes of Health, Office on Smoking and Health, National Centerfor Cronic Disease Prevention and Health Promotion, CDC.

Adapted from Morbidity and Mortality Weekly Report,vol 44,no.28,1995

Articles in this issue

Trends in Cancer Screening-United States, 1987 and 1992
Economic Savings and Costs of Periodic Mammographic Screening in the Workplace
Book Review: Dr. Susan Love's Breast Book, 2nd Edition
Trends in Smoking Initiation Among Adolescents and Young Adults-United States, 1980-1989
Pilot Study Points to Possibly Improved NSCLC Survival With Simultaneous Chemo/RT
DaunoXome Shows Promise as Breast Cancer Treatment
New Agent Blocks HIV Integrase, Another Target for Anti-AIDS Therapy
Topotecan Demonstrates Significant Activity in Small-Cell Lung Cancer
Xerostomia as a Complication of Cancer Treatment
Irinotecan Shown to Be Effective Against Colorectal Cancer
Talk More, Test Less, Panel Urges Health Providers
Docetaxel Said to Be Highly Effective and and Well Tolerated in Advanced Head and Neck cancer.
Trial of Topotecan as First - Line Treatment for Ovarian Cancer Announced
Isolation of New Transmissible Herpesvirus Suggests Additional Therapeutic Approaches for KS
Does Neck Stage Predict Local Control After Irradiation for Head and Neck Cancer?
Related Videos
Experts on CML
Experts on MM
Experts on CML
Experts on MM
KOLs smiling at camera.
KOLs smiling at camera.
Related Content

AVB-001 Receives FDA FTD in Platinum-Resistant Ovarian Cancer

October 3rd 2023

Pipeline Perspectives: Fruquintinib in Metastatic Colorectal Cancer

October 2nd 2023

FDA Approves Pegcetacoplan Injector for Paroxysmal Nocturnal Hemoglobinuria

October 3rd 2023

Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances

September 18th 2023

Alisertib Earns FDA Orphan Drug Designation for Small Cell Lung Cancer

October 2nd 2023

Hypofractionated Vs Standard RT Yields Similar Toxicity in Breast Cancer

October 2nd 2023

AVB-001 Receives FDA FTD in Platinum-Resistant Ovarian Cancer

October 3rd 2023

Pipeline Perspectives: Fruquintinib in Metastatic Colorectal Cancer

October 2nd 2023

FDA Approves Pegcetacoplan Injector for Paroxysmal Nocturnal Hemoglobinuria

October 3rd 2023

Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances

September 18th 2023

Alisertib Earns FDA Orphan Drug Designation for Small Cell Lung Cancer

October 2nd 2023

Hypofractionated Vs Standard RT Yields Similar Toxicity in Breast Cancer

October 2nd 2023

AVB-001 Receives FDA FTD in Platinum-Resistant Ovarian Cancer

October 3rd 2023

Pipeline Perspectives: Fruquintinib in Metastatic Colorectal Cancer

October 2nd 2023

FDA Approves Pegcetacoplan Injector for Paroxysmal Nocturnal Hemoglobinuria

October 3rd 2023

Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances

September 18th 2023

Alisertib Earns FDA Orphan Drug Designation for Small Cell Lung Cancer

October 2nd 2023

Hypofractionated Vs Standard RT Yields Similar Toxicity in Breast Cancer

October 2nd 2023
Related Content
Advertisement

Investigators are assessing AVB-001 as a treatment for those with high-grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube in a phase 1/2 trial.

AVB-001 Receives FDA FTD in Platinum-Resistant Ovarian Cancer

October 3rd 2023
Article

Investigators are assessing AVB-001 as a treatment for those with high-grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube in a phase 1/2 trial.


Arvind N. Dasari, MD, and Cathy Eng, MD, discuss clinical trial data that may support the FDA approval of fruquintinib in metastatic colorectal cancer, and how it may impact the standard of care.

Pipeline Perspectives: Fruquintinib in Metastatic Colorectal Cancer

October 2nd 2023
Podcast

Arvind N. Dasari, MD, and Cathy Eng, MD, discuss clinical trial data that may support the FDA approval of fruquintinib in metastatic colorectal cancer, and how it may impact the standard of care.


Patients with paroxysmal nocturnal hemoglobinuria can now self-administer pegcetacoplan subcutaneously following the FDA’s approval of an injector.

FDA Approves Pegcetacoplan Injector for Paroxysmal Nocturnal Hemoglobinuria

October 3rd 2023
Article

Patients with paroxysmal nocturnal hemoglobinuria can now self-administer pegcetacoplan subcutaneously following the FDA’s approval of an injector.


Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances

September 18th 2023
Podcast

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.


Alisertib will be assessed in patients with small cell lung cancer as part of the phase 2 Study PUMA-ALI-4201.

Alisertib Earns FDA Orphan Drug Designation for Small Cell Lung Cancer

October 2nd 2023
Article

Alisertib will be assessed in patients with small cell lung cancer as part of the phase 2 Study PUMA-ALI-4201.


Data from the FABREC trial support the use of hypofractionated postmastectomy radiotherapy in patients with breast cancer following implant-based reconstruction.

Hypofractionated Vs Standard RT Yields Similar Toxicity in Breast Cancer

October 2nd 2023
Article

Data from the FABREC trial support the use of hypofractionated postmastectomy radiotherapy in patients with breast cancer following implant-based reconstruction.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.